{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:08:57Z","timestamp":1794107337658,"version":"4.8.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:00:00Z","timestamp":1760572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Retin Vitr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intravitreal aflibercept, ranibizumab, and bevacizumab represent the three most widely used anti-VEGF agents for the treatment of neovascular age-related macular degeneration (AMD). The objective of this study is to compare the loading phase effects of these three agents on the macular neovascularization (MNV) area and flow in treatment-na\u00efve eyes affected by neovascular AMD, utilizing optical coherence tomography angiography (OCTA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eighty-four neovascular AMD eyes from eighty-four patients were included in this retrospective study. Twenty-five patients were treated with aflibercept, thirty-four with ranibizumab, and twenty-five with bevacizumab within the initial loading phase preceding a treat-and-extend regimen. All patients underwent a three-monthly injection loading phase and were evaluated at baseline and one month after the loading phase. Best-corrected visual acuity (BCVA), central retinal thickness (CRT), MNV area, and MNV flow area were assessed. MNV parameters were measured using the device-integrated \u201cFlow Area\u201d tool and ImageJ software.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Average baseline BCVA and CRT were 0.60\u2009\u00b1\u20090.22 logMAR and 343\u2009\u00b1\u200946\u00a0\u03bcm, respectively, and did not differ between groups. All three anti-VEGF agents improved anatomical and functional parameters, with no statistically significant differences between treatment groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). Aflibercept showed the most significant CRT reduction (88\u00a0\u03bcm;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), while bevacizumab led to the highest BCVA gain (0.15 logMAR;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). MNV area significantly decreased only in the bevacizumab group (0.26 mm2;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01), and flow area only in the ranibizumab group (0.23 mm2;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). A strong positive correlation between MNV areas and flow areas was found at baseline (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009&gt;\u20090.8) and follow-up (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009&gt;\u20090.9).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Aflibercept, ranibizumab, and bevacizumab demonstrated similar efficacy in reducing MNV area and flow and improving visual and anatomical outcomes after a three-injection loading phase. OCTA-derived flow area measurement may be a valuable and easily accessible tool in monitoring early treatment response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40942-025-00740-y","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:30:50Z","timestamp":1760621450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Aflibercept, ranibizumab, and bevacizumab for macular neovascularization secondary to age-related macular degeneration: a retrospective OCT-angiography study"],"prefix":"10.1186","volume":"11","author":[{"given":"Marco","family":"Lombardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Maccauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"D\u2019Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Grossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Missiroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Cesareo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Ricci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,16]]},"reference":[{"issue":"2","key":"740_CR1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","volume":"2","author":"WL Wong","year":"2014","unstructured":"Wong WL, Su X, Li X, Cheung CMG, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106\u201316.","journal-title":"Lancet Glob Health"},{"issue":"4","key":"740_CR2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.ophtha.2012.10.036","volume":"120","author":"FL Ferris","year":"2013","unstructured":"Ferris FL, Wilkinson CP, Bird A, Chakravarthy U, Chew E, Csaky K, et al. Clinical classification of Age-related macular degeneration. Ophthalmology. 2013;120(4):844\u201351.","journal-title":"Ophthalmology"},{"issue":"5","key":"740_CR3","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","volume":"127","author":"RF Spaide","year":"2020","unstructured":"Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, et al. Consensus nomenclature for reporting neovascular Age-Related macular degeneration data. Ophthalmology. 2020;127(5):616\u201336.","journal-title":"Ophthalmology"},{"issue":"14","key":"740_CR4","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular Age-Related macular degeneration. N Engl J Med. 2006;355(14):1419\u201331.","journal-title":"N Engl J Med"},{"issue":"20","key":"740_CR5","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"364","author":"Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration","year":"2011","unstructured":"Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. 2011;364(20):1897\u2013908.","journal-title":"N Engl J Med"},{"issue":"12","key":"740_CR6","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"JS Heier","year":"2012","unstructured":"Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. Intravitreal Aflibercept (VEGF Trap-Eye) in wet Age-related macular degeneration. Ophthalmology. 2012;119(12):2537\u201348.","journal-title":"Ophthalmology"},{"issue":"2","key":"740_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.ophtha.2016.10.010","volume":"124","author":"GJ Jaffe","year":"2017","unstructured":"Jaffe GJ, Ciulla TA, Ciardella AP, Devin F, Dugel PU, Eandi CM, et al. Dual antagonism of PDGF and VEGF in neovascular Age-Related macular degeneration. Ophthalmology. 2017;124(2):224\u201334.","journal-title":"Ophthalmology"},{"issue":"1","key":"740_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40942-015-0005-8","volume":"1","author":"TE De Carlo","year":"2015","unstructured":"De Carlo TE, Romano A, Waheed NK, Duker JS. A review of optical coherence tomography angiography (OCTA). Int J Retina Vitr. 2015;1(1):5.","journal-title":"Int J Retina Vitr"},{"issue":"4","key":"740_CR9","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.1364\/OE.20.004710","volume":"20","author":"Y Jia","year":"2012","unstructured":"Jia Y, Tan O, Tokayer J, Potsaid B, Wang Y, Liu JJ, et al. Split-spectrum amplitude-decorrelation angiography with optical coherence tomography. Opt Express. 2012;20(4):4710.","journal-title":"Opt Express"},{"issue":"4","key":"740_CR10","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.survophthal.2023.02.004","volume":"68","author":"M Rispoli","year":"2023","unstructured":"Rispoli M, Cennamo G, Antonio LD, Lupidi M, Parravano M, Pellegrini M, et al. Practical guidance for imaging biomarkers in exudative age-related macular degeneration. Surv Ophthalmol. 2023;68(4):615\u201327.","journal-title":"Surv Ophthalmol"},{"issue":"11","key":"740_CR11","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1097\/IAE.0000000000000836","volume":"35","author":"NW Muakkassa","year":"2015","unstructured":"Muakkassa NW, Chin AT, De Carlo T, Klein KA, Baumal CR, Witkin AJ, et al. Characterizing the effect of anti-vascular endothelial growth factor therapy on treatment-naive choroidal neovascularization using optical coherence tomography angiography. Retina. 2015;35(11):2252\u20139.","journal-title":"Retina"},{"issue":"1","key":"740_CR12","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1038\/s41598-023-30146-5","volume":"13","author":"H Matsumoto","year":"2023","unstructured":"Matsumoto H, Hoshino J, Nakamura K, Akiyama H. Two-year outcomes of treat-and-extend regimen with intravitreal Brolucizumab for treatment-na\u00efve neovascular age-related macular degeneration with type 1 macular neovascularization. Sci Rep. 2023;13(1):3249.","journal-title":"Sci Rep"},{"key":"740_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/3751702","volume":"2018","author":"A Miere","year":"2018","unstructured":"Miere A, Oubraham H, Amoroso F, Butori P, Astroz P, Semoun O, et al. Optical coherence tomography angiography to distinguish changes of choroidal neovascularization after Anti-VEGF therapy: monthly loading dose versus pro re Nata regimen. J Ophthalmol. 2018;2018:1\u20137.","journal-title":"J Ophthalmol"},{"issue":"1","key":"740_CR14","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41433-023-02652-3","volume":"38","author":"M Cozzi","year":"2024","unstructured":"Cozzi M, Monteduro D, Esposito RA, Spooner KL, Fraser-Bell S, Staurenghi G, et al. Lesion area progression in eyes with neovascular age-related macular degeneration treated using a proactive or a reactive regimen. Eye. 2024;38(1):161\u20137.","journal-title":"Eye"},{"issue":"1","key":"740_CR15","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ophtha.2014.07.041","volume":"122","author":"K Berg","year":"2015","unstructured":"Berg K, Pedersen TR, Sandvik L, Bragad\u00f3ttir R. Comparison of Ranibizumab and bevacizumab for neovascular Age-Related macular degeneration according to LUCAS Treat-and-Extend protocol. Ophthalmology. 2015;122(1):146\u201352.","journal-title":"Ophthalmology"},{"issue":"2","key":"740_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1136\/bjophthalmol-2014-305149","volume":"99","author":"MK Schmid","year":"2015","unstructured":"Schmid MK, Bachmann LM, F\u00e4s L, Kessels AG, Job OM, Thiel MA. Efficacy and adverse events of aflibercept, Ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis. Br J Ophthalmol. 2015;99(2):141\u20136.","journal-title":"Br J Ophthalmol"},{"key":"740_CR17","doi-asserted-by":"crossref","unstructured":"Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Eyes and Vision Group, editor. Cochrane Database Syst Rev. 2019 Mar 4;2019(3) Available from: https:\/\/doi.org\/10.1002\/14651858.CD005139.pub4","DOI":"10.1002\/14651858.CD005139.pub4"},{"issue":"2","key":"740_CR18","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1586\/17512433.2014.884458","volume":"7","author":"MW Stewart","year":"2014","unstructured":"Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol. 2014;7(2):167\u201380.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"8","key":"740_CR19","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","volume":"123","author":"MG Maguire","year":"2016","unstructured":"Maguire MG, Martin DF, Ying G, shuang, Jaffe GJ, Daniel E, Grunwald JE, et al. Five-Year outcomes with Anti\u2013Vascular endothelial growth factor treatment of neovascular Age-Related macular degeneration. Ophthalmology. 2016;123(8):1751\u201361.","journal-title":"Ophthalmology"},{"key":"740_CR20","doi-asserted-by":"publisher","first-page":"100906","DOI":"10.1016\/j.preteyeres.2020.100906","volume":"82","author":"PS Mettu","year":"2021","unstructured":"Mettu PS, Allingham MJ, Cousins SW. Incomplete response to Anti-VEGF therapy in neovascular AMD: exploring disease mechanisms and therapeutic opportunities. Prog Retin Eye Res. 2021;82:100906.","journal-title":"Prog Retin Eye Res"},{"issue":"6","key":"740_CR21","doi-asserted-by":"publisher","first-page":"4129","DOI":"10.1167\/iovs.15-16735","volume":"56","author":"F Coscas","year":"2015","unstructured":"Coscas F, Coscas G, Lupidi M, Dirani A, Srour M, Semoun O, et al. Restoration of outer retinal layers after Aflibercept therapy in exudative AMD: prognostic value. Investig Opthalmology Vis Sci. 2015;56(6):4129.","journal-title":"Investig Opthalmology Vis Sci"},{"issue":"2","key":"740_CR22","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1080\/15569527.2021.1919136","volume":"40","author":"N Demir","year":"2021","unstructured":"Demir N, Sevincli S, Kayhan B, Sonmez M. Anatomical effects of intravitreal anti-vascular endothelial growth factor injections on inner layers of the lesion-free retina. Cutan Ocul Toxicol. 2021;40(2):135\u20139.","journal-title":"Cutan Ocul Toxicol"},{"issue":"3","key":"740_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/aos.15283","volume":"101","author":"Y Abu Dail","year":"2023","unstructured":"Abu Dail Y, Seitz B, Sideroudi H, Abdin AD. Impact of intravitreal ranibizumab, Aflibercept and bevacizumab on retinal ganglion cell and nerve fibre layer thickness in neovascular age-related macular degeneration. Acta Ophthalmol (Copenh). 2023;101(3):330\u201341.","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"1","key":"740_CR24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/bjophthalmol-2017-311752","volume":"103","author":"E Pilotto","year":"2019","unstructured":"Pilotto E, Frizziero L, Daniele AR, Convento E, Longhin E, Guidolin F, et al. Early OCT angiography changes of type 1 CNV in exudative AMD treated with anti-VEGF. Br J Ophthalmol. 2019;103(1):67\u201371.","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"740_CR25","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1097\/IAE.0000000000000627","volume":"35","author":"KB Freund","year":"2015","unstructured":"Freund KB, Korobelnik JF, Devenyi R, Framme C, Galic J, Herbert E, et al. TREAT-AND-EXTEND REGIMENS WITH ANTI-VEGF AGENTS IN RETINAL DISEASES: A literature review and consensus recommendations. Retina. 2015;35(8):1489\u2013506.","journal-title":"Retina"},{"issue":"7","key":"740_CR26","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.3390\/jcm11071834","volume":"11","author":"F Matonti","year":"2022","unstructured":"Matonti F, Korobelnik JF, Dot C, Gualino V, Soler V, Mrejen S, et al. Comparative effectiveness of intravitreal Anti-Vascular endothelial growth factor therapies for managing neovascular Age-Related macular degeneration: A Meta-Analysis. J Clin Med. 2022;11(7):1834.","journal-title":"J Clin Med"},{"key":"740_CR27","doi-asserted-by":"crossref","unstructured":"Parravano M, Viola F, Nicol\u00f2 M, Vujosevic S, Bianchino L, Sicari E, et al. Real-world evidence of anti-VEGF therapies in patients with neovascular age-related macular degeneration in Italy: the RADIANCE study. Eur J Ophthalmol. 2025;11206721241310628.","DOI":"10.1177\/11206721241310628"},{"issue":"1","key":"740_CR28","doi-asserted-by":"publisher","first-page":"19278","DOI":"10.1038\/s41598-024-70234-8","volume":"14","author":"M Schranz","year":"2024","unstructured":"Schranz M, Bogunovic H, Deak G, Sadeghipour A, Reiter GS, Schmidt-Erfurth U. Linking disease activity with optical coherence tomography angiography in neovascular age related macular degeneration using artificial intelligence. Sci Rep. 2024;14(1):19278.","journal-title":"Sci Rep"}],"container-title":["International Journal of Retina and Vitreous"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00740-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40942-025-00740-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40942-025-00740-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:21:52Z","timestamp":1781612512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40942-025-00740-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["740"],"URL":"https:\/\/doi.org\/10.1186\/s40942-025-00740-y","relation":{},"ISSN":["2056-9920"],"issn-type":[{"value":"2056-9920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,16]]},"assertion":[{"value":"22 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and approved by the Territorial Ethics Committee of Lazio Area 2 (protocol code: 139.25; date of approval: 22\/05\/2025). Informed consent was obtained from all subjects involved in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"111"}}